QUALITY RISK MANAGEMENT FOR SALBUTAMOL PRESSURIZED METERED DOSE INHALERS

The risks for the functional characteristics of Salbutamol pressurized metered dose inhaler (pMDI), such as the uniformity of delivered dose, the distribution of salbutamol particles at the stages of the Andersen impactor (apparatus D), and the respirable fraction, were studied and identified. It is shown that these risks can be associated with the solubility of salbutamol sulfate (SS), the formulation of pMDI, the water content in the SS and ethanol, as well as the particle size distribution of SS. A relationship is shown between the particle size distribution of the SS, the rate of their sedimentation and the performance characteristics of the preparation. The properties of SS crystals are investigated and the possibility of enantiomers presence is shown. The risks associated with the production process, the materials of the primary packaging and the correctness of the quality control procedures are discussed. It is shown that the use of containers made of aluminum alloy EN AW-5052-0 without internal coating does not pose the risk of the release of elemental impurities into the preparation. Unjustified replacement of actuators may pose a risk to the performance characteristics of Salbutamol pMDI and in vitro equivalence as compared with the reference medicinal product.

salbutamol, pressurized metered dose inhaler, performance characteristic, uniformity of delivered dose, fine particle dose, critical quality attribute, risk

1. Compendium 2016 - drugs / Ed. V. N. Kovalenko. K.: MORION, 2016. 2416 s.

2. EMA/INS/GMP/79818/2011 Pharmaceutical Quality System (ICH Q10), 31 January 2011.

3. EMEA/CHMP/167068/2004 - ICH. - Part I: Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 (R2) Pharmaceutical Development). - Part II: Annex to Note for Guidance on Pharmaceutical Development (ICH Topic Q 8 Annex Pharmaceutical Development), June 2009.

4. EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev 1 Guideline on process validation for finished products - information and data to be provided in regulatory submissions, 27 February 2014.

5. EMEA/СHМР/QWP/49313/2005 Corr. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. London, 21 June 2006.

6. EMA/INS/GMP/79766/2011 Quality Risk Management (ICH Q9), 31 January 2011.

7. EudraLex. - The Rules Governing Medicinal Products in the European Union. - Volume 4. EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Available at: http://ec.europa.eu/health/documents/eudralex/vol-4/index en.htm (accessed 15.07.2018)

8. Lyapunov N. A., Bezuglaya E. P., Bovtenko V. A., Stolper Yu. M. Comparative study of the aerodynamic properties of salbutamol aerosols // Development and registration of drugs. 2018. № 1(22). P. 54-61.

9. European Pharmacopoeia. 9th Edition. European Directorate for the Quality of Medicines (EDQM). Council of Europe, 67075 Strasbourg Cedex, France 2016. 4016 p.

10. Lyapunov N. A., Bezuglaya E. P., Bovtenko V. A., Stolper Yu. M. Justification of the new approach to assessing the quality of metered aerosols for inhalation at the stage of their development // Scientific Gazette of Belgorod State University. Series: Medicine. Pharmacy. 2016. № 5(226). V. 33. P. 170-179.

11. Rodriguez-Carvajal J., Roisnel T. Full Prof. 98 and Win PLOTR: New Windows 95/NT Applications for Diffraction. Commission for Powder Diffraction, International Union of Crystallography, Newsletter № 20 (May-August) Summer 1998.

12. USP 36-NF 31. The United States Pharmacopeia and National Formulary 2012 - Copyright © 2012 The United States Pharmacopeial Convention 12601 Twinbrook Parkway, Rockville, MD 20852 - Printed in the United States by United Book Press, Inc., Baltimore, MD. 5642 p.

13. Lyapunov N. A., Bezuglaya E. P., Bovtenko V. A., Stolper Yu. M. New technologies for the production of metered-dose aerosol preparations for inhalation under pressure // Farmakom. 2011. № 1/2. P. 65-74.

14. Bovtenko V. A., Bezuglaya E. P., Stolper Yu. M., Lyapunov N. A. The study of the properties of drugs salbutamol sulfate in the form of metered-dose inhalers under pressure Pharmakom. 2018. № 1. P. 57-70.

15. Lyapunov N.A., Bezuglaya E.P., Bovtenko V.A., Stolper Yu.M. Analytical support of pharmaceutical development of drugs for inhalation under pressure. The choice of composition and packaging // Farmakom. 2008. № 3. P. 65-77.

16. Salbutamol Pressurised Inhalation // British Pharmacopoeia. 2013. V. III.

17. Lippmann M. Regional Deposition of Particles in the Human Respiratory Tract. Comprehensive Physiology. 2011. P. 213-232.

18. CPMP/EWP/4151/00 Rev. 1. Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children and Adolescents. London, 22 January 2009.

19. Groom C. R., Bruno I. J., Lightfoot M. P., Ward S. C. Acta Cryst. 2016. B72. P. 171-179.

20. State Pharmacopoeia of the Russian Federation. XIII ed. T. 2. MZ RF. M., 2015.

21. EMA/CHMP/ICH/353369/2013 ICH guideline Q3D on elemental impurities, 25 July 2016.

22. Registr lekarstvennykh sredstv Rossii. Available at: http://grls.rosminzdrav.ru (accessed 30.10.2017).